Stocks & Investing
Wed, September 18, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 10, 2024
[ 12:00 AM ] - WOPRAI
Thu, August 10, 2023
[ 12:00 AM ] - WOPRAI
Tue, May 9, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 9, 2022
[ 12:00 AM ] - WOPRAI
Wed, March 16, 2022
[ 12:00 AM ] - WOPRAI
Tue, March 1, 2022
Thu, November 11, 2021
[ 12:00 AM ] - WOPRAI
Tue, November 2, 2021
[ 12:00 AM ] - WOPRAI
Thu, October 28, 2021
Tue, October 26, 2021
[ 12:00 AM ] - WOPRAI
Thu, July 29, 2021
[ 12:00 AM ] - WOPRAI
Fri, July 16, 2021
Mon, May 10, 2021
[ 12:00 AM ] - WOPRAI
Fri, May 7, 2021
[ 12:00 AM ] - WOPRAI
Fri, March 26, 2021
[ 12:00 AM ] - WOPRAI
Mon, March 8, 2021
Tue, February 23, 2021
[ 12:00 AM ] - WOPRAI
Mon, January 25, 2021
[ 12:00 AM ] - WOPRAI
Thu, October 1, 2020
[ 12:00 AM ] - WOPRAI
Mon, August 3, 2020
[ 12:00 AM ] - WOPRAI
Fri, May 8, 2020
[ 12:00 AM ] - WOPRAI
Fri, February 28, 2020
[ 12:00 AM ] - WOPRAI
Fri, January 10, 2020
Thu, November 7, 2019
[ 12:00 AM ] - WOPRAI
Fri, May 10, 2019
[ 12:00 AM ] - WOPRAI
Thu, February 14, 2019
Thu, November 9, 2017
Tue, March 14, 2017
[ 12:00 AM ] - WOPRAI
Thu, June 23, 2016 Elliot Wilbur Maintained (ANIP) at Buy with Increased Target to $83 on, Sep 18th, 2024
Elliot Wilbur of Raymond James, Maintained "ANI Pharmaceuticals, Inc." (ANIP) at Buy with Increased Target from $81 to $83 on, Sep 18th, 2024.
Elliot has made no other calls on ANIP in the last 4 months.
There are 2 other peers that have a rating on ANIP. Out of the 2 peers that are also analyzing ANIP, 1 agrees with Elliot's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gregory Fraser of "Truist Securities" Downgraded from Strong Buy to Hold and Decreased Target to $60 on, Wednesday, September 11th, 2024
This is the rating of the analyst that currently disagrees with Elliot
- Oren Livnat of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $94 on, Tuesday, September 17th, 2024
